Company Overview
Establishment Labs Holdings Inc. operates within the healthcare sector, specifically focusing on the medical devices industry, where it manufactures and markets specialized equipment for breast aesthetic and reconstructive plastic surgeries across Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company provides silicone gel-filled breast implants, serving a global market that requires rigorous regulatory compliance and high-precision manufacturing capabilities. In terms of scale, Establishment Labs Holdings Inc. holds a market capitalization of $1.84B and employs approximately 1004 individuals, generating annual revenue of $211.08M over the trailing twelve months. These valuation and revenue figures indicate that the company has established a significant presence in the medical technology landscape, commanding a substantial market value despite operating in a niche segment of plastic surgery. The combination of a broad international footprint and a multi-hundred-million-dollar revenue base suggests the firm is a mature entity within the medical device space, capable of scaling operations while maintaining a large workforce.
Financial Health
The company reported revenue of $211.08M for the trailing twelve months, yet this generated a net income of -$51,064,000 and an EBITDA of -$29,445,000, revealing a significant gap between top-line growth and profitability. This divergence highlights a cost structure where operating expenses and costs of goods sold are currently outpacing gross margins, resulting in a substantial bottom-line loss relative to sales volume. The free cash flow stands at -$41,574,000, which indicates a lack of financial flexibility in the short term as the company is burning through cash reserves to fund operations and growth initiatives. Margin analysis shows a gross margin of 69.3%, suggesting strong pricing power or favorable production efficiency on individual units, while the operating margin of -6.1% and profit margin of -24.2% expose the heavy overhead costs required to run a global medical device business. On the balance sheet, the company holds $75.57M in cash against $264.47M in total debt, resulting in a debt-to-equity ratio of 1123.14, which characterizes the entity as highly leveraged and sensitive to interest rate fluctuations. Despite the high leverage, the current ratio of 3.04 indicates robust short-term liquidity, as current assets significantly exceed current liabilities, providing a buffer against immediate payment obligations. Return on Equity is -133.3% and Return on Assets is -6.9%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate profit, likely due to the aggressive expansion or high R&D spend inherent in the medical device sector.
Valuation Assessment
Valuation metrics for Establishment Labs Holdings Inc. show a P/E Ratio (TTM) listed as N/A due to negative earnings, while the Forward P/E is 305.61, implying that the market prices the stock based on anticipated future profitability rather than current results. The Price to Book ratio is 77.92, indicating that the market values the company at a massive premium over its tangible book value, a common phenomenon for growth-oriented medical technology firms with intangible assets. The Price to Sales ratio stands at 8.70 and the EV/EBITDA is -68.80, suggesting that traditional valuation multiples are distorted by losses and that investors are relying heavily on revenue growth narratives to justify the stock price. Regarding trading ranges, the 52-week high is $83.31 and the 52-week low is $26.56, meaning the current share price sits within a volatile band that reflects significant investor sentiment swings over the past year. The Beta is 0.96, which suggests that the stock's price volatility closely mirrors the broader market, moving in tandem with overall market conditions without exhibiting extreme idiosyncratic risk or defensive characteristics.
Growth & Income
Revenue growth year-over-year is 45.2%, demonstrating rapid expansion in sales volume, whereas earnings growth is N/A because the company is currently unprofitable, implying that top-line revenue is being reinvested into operations rather than generating immediate returns. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which confirms that all available earnings, or rather the absence thereof, are being retained within the business to fuel the high revenue growth rate. Since the firm is a non-dividend payer, the 45.2% revenue surge indicates a strategy focused entirely on market share acquisition and product line expansion rather than income distribution to shareholders. Overall, the growth and income profile is defined by aggressive top-line expansion without current income generation, requiring the market to wait for the company to transition from a cash-burning phase to a profitable one before traditional valuation multiples and dividend metrics become relevant.